Gábor Mikala - Infectious Diseases

Author Information

Gábor Mikala is affiliated with the Department of Hematology and Stem Cell Transplantation at the South Pest Central Hospital-National Institute for Hematology and Infectious Diseases in Budapest, Hungary. His work primarily revolves around hematology, with a keen focus on multiple myeloma and chronic lymphocytic leukemia, as well as the implications of monoclonal gammopathy.

Research Contributions

Gábor Mikala has made significant contributions to the field of hematology, particularly in the study of multiple myeloma and chronic lymphocytic leukemia. His research includes the examination of targeted therapies such as Venetoclax for t(11;14) multiple myeloma and the use of Melflufen or pomalidomide in refractory cases. He has also investigated the detection of ibrutinib resistance in chronic lymphocytic leukemia and the role of cytokeratin 20 in the emergence and severity of acute GvHD. His work bridges clinical trials and real-world data, enhancing our understanding of treatment efficacy and resistance mechanisms.

Aliases

Gábor Mikala is also known by other aliases including G Mikala, G. Mikala, and Gabor Mikala. These variations may appear in different publications and professional references.

Publication and Citation Metrics

Metric	Value
Total Papers	176
Total Citations	3039
H-index	27

Publications:

Targeted Venetoclax Therapy in t(11;14) Multiple Myeloma: Real World Data From Seven Hungarian Centers

DOI: 10.3389/pore.2022.1610276

Year: 2022

Monoclonal Gammopathy with Known Significance in TEMPI Syndrome: Case Report and Minireview of the Literature

DOI: 10.29011/2574-7754.100779

Year: 2022

Melflufen or pomalidomide plus dexamethasone for patients with multiple myeloma refractory to lenalidomide (OCEAN): a randomised, head-to-head, open-label, phase 3 study.

DOI: 10.1016/S2352-3026(21)00381-1

Year: 2022

Decreased Plasma Level of Cytokeratin 20 (KRT20) Is Indicative of the Emergence and Severity of Acute GvHD Irrespective to the Type of Organ Involvement

DOI: 10.3390/biomedicines10030519

Year: 2022

Corneal Densitometry and In Vivo Confocal Microscopy in Patients with Monoclonal Gammopathy—Analysis of 130 Eyes of 65 Subjects

DOI: 10.3390/jcm11071848

Year: 2022

Detection of emerging ibrutinib resistance by flow cytometry in patients with chronic lymphocytic leukemia

DOI: 10.21203/rs.3.rs-1046046/v1

Year: 2021

Detection of Emerging Ibrutinib Resistance by Flow Cytometry in Patients with Chronic Lymphocytic Leukemia

DOI: 10.21203/rs.3.rs-1046046/v2

Year: 2021

Myeloma: A Lot of Progress, Still a Long Way to Go

DOI: 10.3390/cancers13236087

Year: 2021

P-205: PORT (OP-109): Phase 2, randomised, Pharmacokinetic (PK), cross-over study of peripheral vs central intravenous administration of Melflufen in patients with Relapsed/Refractory Multiple Myeloma (RRMM)

DOI: 10.1016/s2152-2650(21)02332-6

Year: 2021

ISATUXIMAB PLUS CARFILZOMIB AND DEXAMETHASONE IN PATIENTS WITH RELAPSED MULTIPLE MYELOMA AND SOFT-TISSUE PLASMACYTOMAS: IKEMA SUBGROUP ANALYSIS

DOI: 10.1016/j.htct.2021.10.334

Year: 2021

What Is the Future of Research on Respiratory Droplets?

What are the Key Components of Infectious Disease Education?

How Does the Innate Immune System Interact with the Adaptive Immune System?

Why is Mosquito Control Crucial?

What is the FDA's Role in Public Health Campaigns?

What are Infectious Diseases?

What is a Rash?

How Does Direct Contact Transmission Occur?

What Role Does Community Engagement Play?

How Can Epigenetics Be Used to Combat Infectious Diseases?

Partnered Content Networks

Relevant Topics